Filing Flows › Nu Skin Enterprises (NUS) › Stock forecast & fair value
Nu Skin Enterprises (NUS) stock forecast and fair value
Nu Skin Enterprises (NUS) trades at $4.65. One analyst's price target is $12.48 (+168%). Across 17 valuation methods the middle fair value is $9.97 (+114%).
Fair value by method
| Method | Low | Point | High | vs price |
|---|---|---|---|---|
| EV/EBITDA vs peers | $6.91 | $9.97 | $13.12 | +114% |
| EV/EBITDA vs peers, weighted | $9.92 | $13.56 | $14.70 | +192% |
| EV/EBITDA vs peers, growth-adjusted | $5.17 | $7.37 | $10.42 | +58% |
| EV/Sales vs peers | $7.09 | $12.45 | $27.02 | +168% |
| EV/Sales vs peers, weighted | $5.06 | $6.99 | $10.03 | +50% |
| EV/Sales vs peers, growth & margin adjusted | $6.32 | $9.91 | $15.39 | +113% |
| Residual income | −$2.22 | −$2.26 | −$2.29 | -149% |
| Analysts' price targets | $12.48 | $12.48 | $12.48 | +168% |
| Shareholder yield (dividends + buybacks) | $7.67 | $8.66 | $9.94 | +86% |
| Tangible book (asset value) | $8.23 | $10.29 | $10.29 | +121% |
Nu Skin Enterprises' latest quarter
Nu Skin Enterprises, Q3 2026: revenue $311M (-15% year over year), operating margin 1.6%, net loss $742K, operating cash flow −$8.1M. The chart follows the revenue to costs, profit and cash.
Questions
What is the price target for NUS stock?
One analyst's 12-month target is $12.48, +168% from $4.65. The average rating is none.
What is Nu Skin Enterprises' fair value?
The fair-value methods on Filing Flows (DCF, Monte Carlo, peer multiples and others) put it between −$2.26 and $51.77, with a middle value of $9.97 against a price of $4.65. Each method's assumptions are on the page.
Does Nu Skin Enterprises usually beat earnings estimates?
It beat the consensus EPS estimate in 20% of the quarters on record.
Is NUS stock a buy?
Filing Flows does not give advice. It shows what analysts expect, what each valuation method implies and the figures behind them, read from SEC filings, so you can judge for yourself.
Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.